At the news
? BEARISHIMPACT 6/10 8-K filed Nov 2, 2026 at 16:06 ET
Emergent BioSolutions reported Q3 2026 total revenue of $110.0M, down 52% YoY from $231.1M, and a GAAP net loss of $32.7M versus net income of $51.2M in Q3 2025. Revenue was within the company's prior guidance range but missed the consensus estimate of $123.2M. The company lowered its full-year 2026 revenue guidance to $600M-$645M from $645M-$675M and its adjusted EBITDA guidance to $110M-$140M from $130M-$150M, citing timing of USG and international MCM sales and a 20%-25% YoY decline in commercial (naloxone) revenues.
- Q3 2026 total revenue of $110.0M, down 52% YoY from $231.1M, missing consensus of $123.2M
- GAAP net loss of $32.7M vs net income of $51.2M in Q3 2025; GAAP diluted EPS of ($0.64) vs $0.91
- Adjusted net loss of $18.7M vs adjusted net income of $65.2M in Q3 2025
- Adjusted EBITDA of ($4.6M) vs $92.6M in Q3 2025; adjusted EBITDA margin of (4)% vs 40%
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access